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Abstract
To reduce the increasing need for corneal transplantation, attempts are currently aiming to
restore corneal clarity, one potent source of cells are multipotent adult progenitor cells
(MAPC®). These cells release a powerful cocktail of paracrine factors that can guide wound
healing and tissue regeneration. However, their role in corneal regeneration has been over-
looked. Thus, we sought to explore the potential of combining the cytoprotective storage
feature of alginate, with MAPC to generate a storable cell-laden gel for corneal wound heal-
ing. 72 hours following hypothermic storage, alginate encapsulation was shown to maintain
MAPC viability at either 4 or 15˚C. Encapsulated MAPC (2 x106 cells/mL) stored at 15˚C pre-
sented the optimum temperature that allowed for cell recovery. These cells had the ability to
reattach to tissue culture plastic whilst exhibiting normal phenotype and this was maintained
in serum-free and xenobiotic-free medium. Furthermore, corneal stromal cells presented a
significant decrease in scratch-wounds in the presence of alginate encapsulated MAPC
compared to a no-cell control (p = 0.018). This study shows that immobilization of MAPC
within an alginate hydrogel does not hinder their ability to affect a secondary cell population
via soluble factors and that these effects are successfully retained following hypothermic
storage.
Introduction
Corneal damage and opacity have been estimated to cause blindness in 8 million people
(c.10% of total blindness) worldwide each year [1]. Corneal stroma constitutes 90% of the cor-
neal structure containing keratocytes, collagen fibrils, and proteoglycans, all of which help
maintain vision [2]. Corneal keratocytes usually remain quiescent and are only activated when
penetrating damage to the tissue occurs [3]. Usually, a sequence of complex biological events
work together to promote corneal wound healing, including cell migration, proliferation,
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extracellular molecule (ECM) disposition and secretion of angiogenesis factors. While corneal
transplantation is the most utilised surgical intervention for treating corneal damage, it still
has significant limitations such as corneal availability and compatibility. Cell therapy is a
promising technique that has shown vast potential, evidenced by an escalating number of
reported cell therapies around the world. Cell therapy has been investigated for the treatment
of a range of diseases; such as, heart disease, neurodegenerative disorders, cancer, limb ische-
mia, and loss of sight, among many others. So far, very few cell-based therapy products have
been approved by the European Medicines Agency and the Food and Drug Administration
(FDA) [4–8].
Multipotent adult progenitor cells (MAPC1) present a promising source of therapeutic
cells. MAPC are derived from a primitive cell population that can be harvested from bone mar-
row, muscle and brain [9]. MAPC are a more primitive cell population than mesenchymal
stem cells (MSCs), whilst they imitate embryonic stem cells characteristics they still retain
adult stem cells potential in cell therapy. In vitro, MAPC demonstrated a vast differentiation
potential to adipogenic, osteogenic, neurogenic, hepatogenic, hematopoietic, myogenic, chon-
drogenic, epithelial, and endothelial lineages. A key feature of MAPC is that they show large
proliferative potential in vitro without losing their phenotype [10]. The therapeutic potential
of MAPC has been documented in many diseases such as ischaemic stroke [11], graft versus
host disease [12], acute myocardial infarct [13], organ transplant [14] bone repair and
myelodysplasia [15–17]. MAPC have also been shown to enhance bone formation, promote
neovascularisation, and have immunomodulatory effects [18, 19]. Therefore, they may have
significance for corneal wound healing as indicated in previous studies, including the docu-
mented potential for MSC-derived immunomodulatory growth factors such as tumor necrosis
factor-inducible gene 6 protein (TSG-6) to improve corneal transparency following wounding
[20].
There are many important considerations for the successful implementation of cell-based
therapy including how the cells are delivered, but also maintained at the site of repair. Cell
delivery would include cell transportation from the laboratory to the treatment site and direct
application of the cells to the patient. Hydrogels offer a solution to both of these processes as
they are capable of retaining cells within a highly hydrated environment whilst being strong
enough to resist immediate damage in a physiological environment and subsequent release of
the cells during application on the patient. Thus, encapsulation of therapeutic cells within a
hydrogel offer improvement in storage, transportation and delivery. Hydrogels formed from
sodium alginates are found in nature and are readily extracted from brown seaweed [21]. Algi-
nate hydrogels have excellent safety and toxicity records, as such, they have been used widely
in therapy [22], wound dressings [23], but also in protein and cell immobilization [24, 25]. The
relative simplicity and cell-friendly nature of alginate hydrogel gelation have strengthened its
position as a leading biomaterial in cell therapy [26]. Recently alginate encapsulation has been
shown to offer protection to MSCs when exposed to hypothermic temperatures for prolonged
periods (days to weeks) [23, 24]. It was also shown that MSCs had the optimum viable recovery
at 15˚C when encapsulated in alginate [27]. Therefore, alginate provides a simple, low-cost
alternative to cryopreservation for short-term storage and transportation including both cell
retrieval to manufacturing site and subsequent delivery to the treatment center. Furthermore,
such an approach may offer greater flexibility in patient scheduling and transportation. Inter-
estingly, the ability for alginate hydrogels to retain encapsulated cells inside the body in a func-
tional state, could work in combination with its ability to preserve cells during hypothermic
storage to create a storable cell-laden gel. Such a medical device could be manufactured cen-
trally, then shipped and stored at hypothermic temperatures before being applied as hydrogel
bandage containing therapeutic cells to directly affect a superficial wound. Unlike traditional
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approaches to cell therapy, the cells could remain encapsulated within the bandage and induce
wound healing response via the release of paracrine growth factors. Thus, within this study, we
investigated the potential of alginate-encapsulation of MAPC to maintain cell viability, mor-
phology, and ability to affect the closure of an in vitro corneal stromal scratch-wound via para-
crine factors following 72 hours of hypothermic storage at 4 and 15˚C.
Materials and methods
Ethics
Corneal tissues were obtained as by-products of grafting procedures, and kindly provided by
Dr Franscisco Figueiredo, MD FRCOphth, Royal Victoria Infirmary Newcastle, UK, following
informed consent in accordance with Newcastle University and Newcastle-upon-Tyne Hospi-
tal Trust Research Ethics Committees guidelines. Human multipotent adult progenitor cells
(MAPC) were obtained in collaboration with ReGenesys, Belgium. MAPC were obtained with
consent from a healthy donor.
Human corneal stromal cells isolation and expansion
Human corneal stromal cells were extracted from the excised corneal rings of healthy human
cadaveric donors at the time of corneal transplantation, Corneal tissues were minced using
scalpel after debriding epithelial and endothelial cells. Stromal cells were extracted via enzy-
matic digestion using Dulbecco’s Modified Eagle Medium (DMEM/F12) (ThermoFisher Sci-
entific, Loughborough, UK) supplemented with 5% fetal bovine serum (FBS), 1% penicillin-
streptomycin (ThermoFisher Scientific) and 2 g/L collagenase type I (Sigma-Aldrich, UK). Tis-
sues were then incubated in a humidified incubator (37˚C, 5% CO2) for 5 hours under rota-
tion. The cells were subsequently dissociated with 0.25% Trypsin-EDTA (ThermoFisher
Scientific) solution for 10 min and filtered through a 40 μm EASYstrainer™ (Greiner Bio-One,
UK). Lastly, the solution was neutralized using the DMEM/F12, and centrifuged at 1500 xg for
5 min followed by re-suspension and seeding in a tissue culture flask (ThermoFisher Scientific)
with DMEM/F12 and immediately placed inside the incubator with media change every two
days. At 80% confluence, cells were dissociated using TrypLE™ express enzyme (ThermoFisher
Scientific) and expanded for the experiments, and cells were used up to passage 4. For the start
of the experiment, corneal stromal cells were plated in a 6-well plate at a density of 2 x 105 cells
per well with DMEM/F12 for one day. Followed by a medium change to serum-free DMEM/
F12 supplemented with 1 x 10−3 M L-Ascorbic acid (Sigma-Aldrich), Insulin-Transferrin-Sele-
nium (ITS-G) 1:100 (Invitrogen) and penicillin/streptomycin 1% (SFM).
MAPC collection and isolation
MAPC were obtained in collaboration with ReGenesys, Belgium. Briefly, the cells were isolated
according to previously described methods [28] from a single bone marrow aspirate. MAPC
were expanded and maintained in xenobiotic-free growth medium (XF MAPC medium,
ReGenesys, Heverlee, Belgium). Our cells expressed characteristic morphological features of
MAPC as described previously by Crabbe´ et al [29] and stored in liquid nitrogen until
required. The cells, once thawed, were seeded at 2 x 103 cells per cm2 on CellBIND tissue cul-
ture plastic (Sigma-Aldrich) and maintained in XF MAPC medium in a humidified incubator.
Once cells had reached 80% confluence, they were detached using TrypLE Express Enzyme to
harvest the cells prior to encapsulation in alginate. Cell number was assessed by incubating
them with 1 μM Calcein-AM (CAM) and 2 μM Ethidium Homodimer-1 (EthD-1) (Thermo
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Fisher Scientific) for 15 minutes before counting viable (CAM+) and dead (EthD-1+) cells
using a Countess II FL automated cell counter (Invitrogen).
MAPC encapsulation and storage
A solution of 0.5 ml 2.4% (wt/vol) sodium alginate (NovaMatrix, FMC, Norway) containing a
suspension of 1 x 106 cells was prepared in SFM or XFM. This solution was then gelled by
crosslinking the alginate using an excess of 102 mM calcium chloride within disc-shaped
molds (thickness 1mm, diameter 24mm) as previously described [30] (Fig 1A). The formed
discs containing encapsulated MAPC were washed briefly with sterile phosphate buffered
saline (PBS) (Sigma-Aldrich) and then transferred to either 2ml cryovials (with cell only con-
trols) with 1 ml XFM or to a transparent Transwell with 0.4 μm pore size (Greiner Bio-One
LTD, UK) (with gel only controls) with SFM within a 6 -well plate and sealed (by an airtight
cap or parafilm respectively) and kept within a polystyrene box placed in a cooled incubator
set to either 4˚C or 15˚C (Fig 1B). The gelled discs for subsequent experiments were immedi-
ately used following 72 hours of hypothermic storage at 4˚C and 15˚C. Following hypothermic
storage, the gels containing cells were briefly allowed to equilibrate to room temperature
before further use. Gel only controls (i.e. no cells) were treated in the same conditions as
described above.
Cell release and viability assessment
The encapsulated MAPC were released for viability assessment. Cells were released by dissolv-
ing the alginate gel using 3 mL 100 mM trisodium citrate (Sigma-Aldrich) for 5 minutes at
room temperature. Cell suspension was further diluted with 7 ml PBS before separating cells
by centrifugation and dissociating them with 0.2 ml TrypLE™ Express enzyme for 5 minutes
(due to aggregation of cells at this stage in the control, non-encapsulated samples). An equiva-
lent volume (0.2 ml) of media was then added, and cells were carefully re-suspended prior to
counting. The number of viable cells released was enumerated by incubating cells with 1 μM
Calcein-AM and 2 μM EthD-1 for 15 minutes at 37˚C before counting. The cell only control
samples were treated using the same method as the encapsulated cells.
MAPC attachment and functional cell recovery assessment
Following 72 hours storage, the released MAPC were counted and plated at 2 x 104 cells/cm2
in a CellBIND (Sigma-Aldrich) 24-well plate and incubated for 24 hours in a humidified incu-
bator (37˚C, 5% CO2) before capturing images. Attached cell number was assessed using the
alamar blue assay. After 1 hour of incubation at 37˚C, fluorescence was taken at an excitation
of 545 nm and emission of 590 nm using Varioskan™ LUX Multimode Microplate Reader
(ThermoFisher Scientific). Plates were then stained with methylene blue to assess cell number
as previously described [31]. After washing with sterile PBS, absorption was measured at 650
nm using Infinite F50 plate reader (Tecan Life Sciences, UK). Cell number was assessed using
a standard curve produced from non-stored cells. Attachment efficiency was calculated as the
number of attached cells divided by the number of seeded cells. Functional cell recovery was
calculated as the number of viable cells multiplied by the attachment efficiency.
Scratch-wound assay
Monolayers of human corneal stromal cells were grown to 90% confluence in a 6-well plate,
serum-starved for three days and briefly washed with PBS prior to scratching using 1 ml
micropipette tip. The scratch-wound was followed by a wash twice with PBS to remove any
Multipotent adult progenitor cell in corneal stromal wound healing
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Fig 1. A schematic representation of the encapsulation and storage process of alginate with or without MAPC. (A) The initial
gelling of the alginate prepared by transferring the mixed alginate with or without MAPC into the CaCl2 masked filter paper and left
for two minutes before allocating the gel into 4 ml CaCl2 for final gelling. (B) The formed encapsulations are either stored in a
cryovials or in an air tight chamber for 72 hours at (4 and 15˚C). (C) Following corneal stromal cell scratch-wound induction, the gel
is situated on the upper compartment of the transwell to avoid direct contact between the gel and the corneal stromal cells monolayer.
MAPC, Multipotent adult progenitor cells; SFM, serum-free DMEM:F12 medium; XFM, xenobiotic-free MAPC medium.
https://doi.org/10.1371/journal.pone.0202118.g001
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cellular debris. The scratched cell monolayer was then co-cultured in the presence of encapsu-
lated MAPC after storage at 4˚C and 15˚C, for 40 hours (Fig 1C). The Transwell membrane
prevents direct contact by physically separating the scratched cell monolayer and the alginate
hydrogel containing the MAPC. The rate of wound (scratch) closure was quantified using a
holographic microscope, Iprasense Cytonote (IPRASENSE, Clapiers, France) that employs
lensless imaging technology for real-time monitoring of the cells. Images collected at different
time points were processed using ImageJ 1.50e software. The wound areas were manually mea-
sured using Polygon selection tool and analyzed using measure plugin. Data were collected
from at least three independent biological donors and two technical repeats for each donor.
Assessment of collagen production
Following wound healing, corneal stromal cells were gently washed with warm PBS before fix-
ing with 70% ice-cold ethanol for 10 minutes and incubated overnight with Picro-Sirius Red
stain (Sigma-Aldrich) as previously described [32] with gentle agitation to allow for equilib-
rium staining of the cells. Afterwards, the plates were thoroughly washed with deionized water
to remove the excess dye before adding 1M sodium hydroxide (Sigma-Aldrich) with gentle
agitation. Absorbance was measured at 490 nm to measure total collagen amount. Data were
normalized to cell number measured using Alamar blue taken at the same time point, fluores-
cence taken at 540–580 nm. Collagen amount was calculated as the total collagen produced
divided by the final cell number.
Statistical analysis
Statistical Analysis was carried out using GraphPad Prism (V6.00) software (GraphPad Soft-
ware, Inc, California, USA). Data are conveyed as the mean of values from at least three dis-
tinct donors ± SEM. Comparisons of statistical values were analyzed using two-way repeated
measures of variance ANOVA, and Tukey’s multiple comparisons tests p-values < 0.05 were
considered significant (, p< 0.05; , p< 0.01; , p< 0.001).
Results
Xenobiotic-free medium promotes morphology and survival of MAPC
Starting with exploring the effect of XFM media on MAPC cultures phenotype, MAPC thawed
from liquid nitrogen seeded in a 2000 cells/cm2 density and grown and maintained in XFM
medium for 72 hours at 37˚C were analyzed for morphology, proliferation, and viability.
Phase-contrast micrographs showed that cells acquired their typical small, spindle-shaped,
fibroblastic-like morphology [33, 34]. This shape persisted over three days in culture as was
previously shown [28] (Fig 2A). In regards to proliferation, at day three, there was an increase
in live cell number compared to the starting seeding density (Fig 2B). Cells viability were ana-
lyzed by live/dead double staining at day three, where it showed an average viability of 95 ± 1%
of cells.
Hypothermic storage preserve encapsulated MAPC viability and cell
recovery
In order to quantify the effect of hypothermic storage on cell viability, we encapsulated 1 x 106
MAPC in 1.2% alginate discs and stored them at 4 or 15˚C for 72 hours with XFM medium.
Viable cell recovery of encapsulated MAPC were compared with non-encapsulated (controls)
MAPC samples. Alginate encapsulated and stored MAPC at both 4˚C and 15˚C yielded a simi-
lar viable cell recovery (approximately 66%) whilst viable cell recovery from control (non-
Multipotent adult progenitor cell in corneal stromal wound healing
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encapsulated) at 4˚C was significantly lower (approximately 40%). Control cells stored at 15˚C
showed no significant difference compared to encapsulated MAPC in viable cell recovery
immediately following release (Fig 3A). However, following reattachment significant differ-
ences were seen between controls and encapsulated at both 4 and 15˚C, suggesting that a con-
siderable number of cells that were shown to be viable by Calcein AM staining, immediately
Fig 2. MAPC morphology. (A). Following 3 days’ expansion the cells presented normal spindle-shaped fibroblastic-like cells. Cells had an increase in
their proliferation evident by the increase in cell number compared to day1 (B). Scale bar = 200 μm. Values are expressed as means ± SEM from 3
separate experiments with unpaired t test (p< 0.001).
https://doi.org/10.1371/journal.pone.0202118.g002
Fig 3. The effect of alginate-encapsulation on the hypothermic preservation of MAPC. MAPC were stored at 4 or 15˚C temperatures either
encapsulated (Encaps.) or non-encapsulated (Ctrl.) for 72 hours before assessing viable cell recovery (A). Following return to cell culture environment
for 24 hours, cell attachment efficiency (B) was assessed. Functional cell number (C) was calculated as the viable cell recovery multiplied by the
attachment efficiency. Cell morphology (D) was retained following release from encapsulation and plated for an additional 24hrs under normal
conditions. Scale bar = 200 μm. Values are expressed as means ± SEM from 3 separate experiments with asterisks representing significance from control
values (p< 0.001; p< 0.01; p< 0.05).
https://doi.org/10.1371/journal.pone.0202118.g003
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following release were actually not able to reattach, proving functionality had been preserved
by alginate encapsulation (Fig 3B). A further measure of cell functionality was attempted by
multiplying the values of cell viability by cell attachment efficiency (Fig 3C). This clearly
showed a significant protective effect given by alginate encapsulation for hypothermic
storage of MAPC, with 15˚C offering a slightly higher value than 4˚C for encapsulated
cells and a significantly greater effect between 4 and 15˚C controls. After 24 hours in culture
encapsulated cells stored at both 4 and 15˚C had attached readily to tissue culture plastic and
adopted a normal spindle shaped fibroblast-like morphology indistinguishable from non-
stored cells (Fig 3D).
Encapsulated MAPC promote scratch-wound closure
The effect of encapsulated MAPC on corneal wound healing was examined using a standard
scratch-wound assay (Fig 4). Accordingly, the serum-starved corneal stromal cells, as a conflu-
ent monolayer, were scratched and incubated in SFM in the presence of encapsulated MAPC
(previously stored 4 and 15˚C) for two days under normal culture conditions. Immediately fol-
lowing the scratch, cells began migrating to the cell-free area. Wound area closure of human
corneal stromal cells was effectively improved in the presence of encapsulated-MAPC when
compared to the controls (Fig 5A). At 20 hours, post-scratch, the cultures treated with encap-
sulated MAPC previously stored for 3 days at 15˚C, exhibited a significant increase in wound
closure compared to the alginate only control (p = 0.0018) (Fig 5B). Similarly, encapsulated
MAPC previously stored at 4˚C also significantly increased wound closure compared to algi-
nate controls at 20 hours (p = 0.0002) (Fig 5C). Encapsulated MAPC at 15˚C showed similar
improvement in wound closure compared to 4˚C storage (Fig 5D). Conversely, the presence of
alginate only control in scratch-wound culture appears to attenuate the rate of wound healing
compared to medium only (SFM) controls (Fig 5E).
Collagen production
Next, we measured collagen deposition 72 hours post-scratch (at which point all scratches
were 100% confluent). Using Picro-sirius red staining we analyzed collagen production from
corneal stromal cells (Fig 5A). 72 hours post-scratch, the total collagen amounts were found to
be 48.2 mg ± 3.0 in SFM control, whereas increased amounts were found in cultures supple-
mented with 5% FBS (control) 76.6 ± 14.6, whilst cells co-cultured with encapsulated MAPC
were also found to have increased collagen production (62.5 mg ± 19.4 and 61.0 mg ± 13.1
when exposed to 15˚C and 4˚C stored encapsulated MAPC respectively). Interestingly the algi-
nate alone (gel only control) also showed a similar increase 67.2 mg ± 12.7. However, no signif-
icant differences were found among the treatment groups. Cell number was also measured
using Alamar blue assay after 72 hours of initial scratching (Fig 5B). Compared to the initial
seeding density of 2x 105 cells, it was found that corneal stromal cell number increased slightly
to 2.1x 105 ± 0.17 in SFM, decreased slightly to 1.8 x 105 ± 0.32 in presence of alginate controls,
and increased to 3.1 x 105 ± 0.1 and 2.2 x 105 ± 0.88 in the presence of 15 and 4˚C stored
MAPC respectively. As expected adding serum to the media increased corneal stromal cell
number considerably (5.4 x 105 cells ± 0.81). Due to the differences in cell number a normal-
ised measure of collagen disposition was taken by dividing the total collagen amount by the
total final cell number to measure collagen production per 1 x 105 cells (Fig 5C).
Discussion
MAPC have previously been shown to have promising therapeutic immunoregulatory effects
driven ostensibly by their ability to produce paracrine effector molecules [35]. As such the
Multipotent adult progenitor cell in corneal stromal wound healing
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Fig 4. The effect of encapsulated MAPC on corneal wound healing. (A) Representative images using time-lapse microscopy of the
scratch-wound of corneal stromal cells treated with serum-free medium (SFM), alginate, or 1 x 106 MAPC alginate + MAPC at time
points 0, 20, 30 and 40 hours. Treatments were stored for 72 hours at 15˚C (B) or 4˚C (C), p-value for the comparison between
alginate and alginate + MAPC. Comparison between the encapsulated MAPC at different storage temperatures (D), and alginate
only controls at different temperatures compared to SFM control (E). Values are presented as mean ± SEM from 3 separate
experiments with asterisks representing significance between values (, p<.0001; , p<.001; , p<.01; , p<.05). Scale
bars = 300 μm.
https://doi.org/10.1371/journal.pone.0202118.g004
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secretory behavior of these cells has successfully shown to be influential in the treatment of a
variety of clinical conditions, such as hind limb ischemia [36], multiple sclerosis [37], myelo-
dysplastic syndrome [16], acute ischemic stroke [11], and bone repair [33]. However, unlike
MSCs, MAPC have not yet been tested in vitro on corneal stromal cell growth. MAPC have
shown many similarities to MSCs [38]. A number of recent papers have described the para-
crine effect of MSCs on a variety of corneal wounds in vitro and in vivo [39, 40]. An important
aspect of MSCs is their anti-inflammatory effects, which could inhibit inflammation in the
damaged tissue [41, 42]. This was demonstrated in numerous animal models following corneal
chemical burn. For example, MSCs-treated rat corneas were found to reduce the levels of
matrix metalloproteinase-2 (MMP-2), interleukin-2 (IL-2) [43] and interferon-y (IFN-y) [20].
Another key factor found to reduce inflammation in a mouse corneal wound model is TSG-6
Fig 5. Collagen amount produced 72 hours post-scratch in corneal stromal cell cultures. (A) Total collagen amount measured using Picro-sirius red
staining. (B) Cell number measured using Alamar blue assay. (C) Collagen amount normalized to cells number. Values are presented as the
mean ± SEM of three different human corneal stromal cell donors.
https://doi.org/10.1371/journal.pone.0202118.g005
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[44]. It has also been reported that MSCs can restore corneal transparency and reduce neovas-
cularization following wounding in a rabbit corneal model, where MSCs were found to reduce
corneal opacity and neovascularization via reduction in matrix metalloproteinase-9 (MMP-9),
α-smooth muscle actin (α-SMA), transforming growth factor-β1 (TGF-β1) and vascular endo-
thelial growth factor (VEGF) levels [42, 45]. Also, the therapeutic effect of MSCs were shown
on chemical injuries of the cornea using a range of delivery hydrogels such as nanofiber scaf-
fold [46], amniotic membrane [43], and polysaccharide hydrogel [47].
Within the first part of the present study, we set out to investigate if the clinically relevant
cell line, MAPC, can maintain viability and function following encapsulation within an algi-
nate hydrogel and if the hypothermic storage (at 4 and 15˚C) of these cells is possible without
compromising their function and viability. Sodium alginate has been used to preserve MSCs
in ambient and hypothermic temperatures where it was found that any small changes in tem-
perature could affect cells viability and recovery [48, 49]. It was also shown that MSCs main-
tain their viability and function following storage and release from encapsulation [27]. Hence,
we assessed MAPC viability and cell adhesion following storage and release from encapsula-
tion, as they can be considered a therapeutically robust cell that could possibly assist directly in
the repair of the cornea via release of paracrine factors alone. Indeed, our data support this
hypothesis as the MAPC were shown to remain viable and functional following alginate encap-
sulation and hypothermic storage at both 4 and 15˚C for 72 hours. Prominently, alginate was
shown to have a key role in maintaining MAPC survival and function compared to non-
encapsulated MAPC. Despite the absence of serum in encapsulation, cells showed high func-
tional recovery and efficiency. Morphologically, MAPC are spindle-shaped fibroblastic-like
cells, with large doubling potential and multilineage differentiation [48, 49]. In agreement with
the literature [19, 28, 29], MAPC grown in culture showed similar morphology, importantly,
there was no change in this morphology (after storage) indicating that the cells had not under-
gone any changes. This is supported by our previous work in which adipose-derived MSCs
were shown not have remained undifferentiated following the same storage regime
Here we sought to demonstrate for the first time that alginate encapsulated MAPC, follow-
ing hypothermic storage, maintain the ability to release soluble factors in response to the envi-
ronmental cues when returned to normthermia. Thus, in the second part of our study, a
simple scratch assay was employed to mimic a corneal stroma wound in vitro. The data showed
alginate encapsulated MAPC to have a significant effect on scratch closure rates over the first
30 hours. Moreover, this could only be attributed to the ability of encapsulated MAPC to
release soluble factors from within the scaffold as the cells were unable to migrate out of the
hydrogel. Interestingly the presence of alginate gel (control) in wound-healing cultures was
shown to have attenuated the rate of wound healing and cell proliferation whilst increasing
collagen production. Ion-exchange reaction happens when alginate is present in culture
between the calcium ions in the alginate and the sodium ions in the medium [50, 51]. Upon
reaching a certain degree of absorption of calcium, alginate starts to swell and dissolved par-
tially, which could explain the effect of alginate control on the corneal stromal wound-healing.
Corneal stromal wound response involves a sequence of events that aim to fix and return
the cornea to its normal structure and function. Upon corneal stromal injury, the normally
inactive corneal stromal keratocytes differentiate to myofibroblasts to synthesize collagen and
extracellular matrix components. The activated myofibroblasts express aSMA, vimentin and
desmin to repopulate the wound via migration and proliferation [52, 53]. Growth factors are
produced in this wound, and are well known to play an important role in wound healing i.e.
TGF-ß, basic fibroblast growth factor (FGF-2) and platelet-derived growth factor (PDGF)
[54]. TGF-ß effects the production of ECM components such as collagen, laminin and fibro-
nectin, also it effects fibroblasts proliferation. Upon wound closure, myofibroblasts suppress
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their alpha SMA, vimentin and desmin expression [52, 55]. In our system, it is unknown if
encapsulated MAPC produced TGF-ß to activate the keratocytes to myfibroblasts to enhance
their migration and proliferation. However, as it was shown that MAPC have a favorable effect
on the scratch-closure in a non-contact system, this indicates that MAPC do produce soluble
factors compared to the controls. We suggest that these growth factors may include hepatocyte
growth factor (HGF) and keratinocyte growth factor (KGF) that are known to be important in
corneal stromal wound healing [53].
Collagen is produced by fibroblastic cells in response to wounding. Following in vivo cor-
neal stromal injury, collagen type I and III deposition increases at the wound site, depending
on the wound type this deposition could be delayed [56, 57]. This could explain collagen dispo-
sition we see experimentally within our simple scratch assay. The data shown suggests that
cells produce less collagen when they are migrating (as shown in Fig 4). This resulted in low
collagen expression per cell in serum containing media (as cells were highly proliferative) and
high collagen expression per cell in alginate alone (where cells did not proliferate), indeed it
has been suggested that calcium alginate improves collagen production in wound closure [58,
59]. However, in the presence of MAPC and, the data show a combination of migration and
increased collagen expression, which although not shown here as significant could still prove
useful in wound healing.
Although these results provide compelling evidence that MAPC encapsulated in alginate,
stored at hypothermic temperatures, and applied to human corneal stromal cells enhance
the rate of healing, the underpinning paracrine mechanism remains unclear. As mentioned
before, MAPC have similarities to MSCs, and it is known that MSCs do express TGF-β, HGF,
FGF, and TSG-6, which in turn can affect cell proliferation and migration, while improving
corneal healing [60, 61]. Thus, we would expect these factors to be also released from MAPC
in response to corneal wound.
Conclusion
Alginate encapsulation significantly improved functional cell recovery following storage at
both 4 and 15˚C. Alginate encapsulated MAPC enhance the rate of wound closure in human
corneal stromal cells in vitro. The wound healing effects of encapsulated MAPC is enhanced
following hypothermic storage. Overall, the work lends considerable evidence to the novel
concept of a storable cell-laden gel with the caveat that this needs to be investigate within an
in vivo setting to confirm our hypothesis that alginate encapsulated MAPC have the ability to
improve wound healing and consequently reduce corneal scar formation.
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